Celyad Oncology Stock Forecast, Price & News

+0.19 (+3.58 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume19,210 shs
Average Volume40,105 shs
Market Capitalization$78.13 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CYAD News and Ratings via Email

Sign-up to receive the latest news and ratings for Celyad Oncology and its competitors with MarketBeat's FREE daily newsletter.

Celyad Oncology logo

About Celyad Oncology

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T (CAR-T) cell-based therapies for the treatment of cancer. Its lead product candidates includes CYAD-101, an allogeneic CAR-T candidate that is in Phase 1 clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T therapy that is in Phase 1 clinical trial for the treatment of hematological malignancies and solid tumors. The company's preclinical candidates, include allogeneic CAR-T candidate for the treatment of solid tumors; CYAD-221, shRNA based allogeneic CAR-T candidate to treat B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting natural killer group 2D ligands (NKG2D) and an undisclosed membrane protein. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.33 out of 5 stars

Medical Sector

826th out of 2,100 stocks

Pharmaceutical Preparations Industry

404th out of 831 stocks

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Celyad Oncology (NASDAQ:CYAD) Frequently Asked Questions

Is Celyad Oncology a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celyad Oncology in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Celyad Oncology stock.
View analyst ratings for Celyad Oncology
or view top-rated stocks.

What stocks does MarketBeat like better than Celyad Oncology?

Wall Street analysts have given Celyad Oncology a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Celyad Oncology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Celyad Oncology's stock price been impacted by COVID-19 (Coronavirus)?

Celyad Oncology's stock was trading at $7.85 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CYAD shares have decreased by 29.9% and is now trading at $5.50.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CYAD?

3 Wall Street analysts have issued twelve-month price targets for Celyad Oncology's shares. Their forecasts range from $17.00 to $17.00. On average, they anticipate Celyad Oncology's stock price to reach $17.00 in the next year. This suggests a possible upside of 209.1% from the stock's current price.
View analysts' price targets for Celyad Oncology
or view top-rated stocks among Wall Street analysts.

Who are Celyad Oncology's key executives?

Celyad Oncology's management team includes the following people:
  • Mr. Michel E. J. Lussier BME, M.B.A., M.S., MS BME, MBA, Co-Founder & Chairman (Age 65, Pay $85.35k)
  • Mr. Filippo Joseph Petti, CEO, CFO & Director (Age 45, Pay $762.17k)
  • Dr. David Edward Gilham, Chief Scientific Officer (Age 56)
  • Sara Zelkovic, Communications & Investor Relations Director
  • Mr. Philippe Dechamps, Chief Legal Officer & Corp. Sec. (Age 51)
  • Mr. Philippe Nobels, Chief HR Officer & VP of HR (Age 55)
  • Dr. Stephen Rubino M.B.A., Ph.D., Chief Bus. Officer (Age 63)
  • Dr. Peggy Sotiropoulou, Head of R&D
  • Mr. Thomas Lequertier, Head of Cell Therapy Manufacturing Unit
  • Dr. Charles Q. Morris, Chief Medical Officer (Age 56)

Who are some of Celyad Oncology's key competitors?

What other stocks do shareholders of Celyad Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celyad Oncology investors own include Galapagos (GLPG), Cellectis (CLLS), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), ChromaDex (CDXC), bluebird bio (BLUE), SCYNEXIS (SCYX), Neurocrine Biosciences (NBIX), AbbVie (ABBV) and argenx (ARGX).

When did Celyad Oncology IPO?

(CYAD) raised $99 million in an initial public offering (IPO) on Friday, June 19th 2015. The company issued 1,400,000 shares at $70.98 per share. UBS Investment Bank and Piper Jaffray acted as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers.

What is Celyad Oncology's stock symbol?

Celyad Oncology trades on the NASDAQ under the ticker symbol "CYAD."

Who are Celyad Oncology's major shareholders?

Celyad Oncology's stock is owned by a variety of retail and institutional investors. Top institutional investors include Victory Capital Management Inc. (5.28%) and Morgan Stanley (0.17%).

Which major investors are selling Celyad Oncology stock?

CYAD stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., and Morgan Stanley.

How do I buy shares of Celyad Oncology?

Shares of CYAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Celyad Oncology's stock price today?

One share of CYAD stock can currently be purchased for approximately $5.50.

How much money does Celyad Oncology make?

Celyad Oncology has a market capitalization of $78.13 million and generates $10,000.00 in revenue each year. The company earns $-19,650,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis.

How many employees does Celyad Oncology have?

Celyad Oncology employs 87 workers across the globe.

What is Celyad Oncology's official website?

The official website for Celyad Oncology is

Where are Celyad Oncology's headquarters?

Celyad Oncology is headquartered at RUE EDOUARD BELIN 12, MONT-SAINT-GUIBERT C9, 1435.

How can I contact Celyad Oncology?

Celyad Oncology's mailing address is RUE EDOUARD BELIN 12, MONT-SAINT-GUIBERT C9, 1435. The company can be reached via phone at (210) 039-4100.

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.